Other Briefings
India’s Immigration and Foreigners Bill, 2025: What Businesses Need to Know
India’s Immigration and Foreigners Bill 2025 introduces major immigration reforms to boost ease of doing business, attract foreign investment, streamline visa processes, and enhance digital immigration management systems.
India’s Digital Competition Bill Advances with Industry Insights
India is assessing stakeholder feedback on its Draft Digital Competition Bill, underscoring its aim to establish balanced legislation and equitable digital market practices.
India’s Passport Rules 2025: Key Changes You Need to Know
India updates passport rules in 2025 with stricter documentation, digital upgrades, and privacy enhancements for individuals and businesses.
Biometric Authentication for GST in India: Everything You Need to Know
India now allows select GST registration applicants to complete biometric verification at GSK within their home state, effective March 3, 2025.
Understanding the New Tax Residency Rules for NRIs
India’s Income Tax Bill 2025 updates tax residency rules, including a new 120-day rule for high-income NRIs and PIOs. Learn how these changes may impact your tax status from April 1, 2026.
BRSR Reporting in India: Key Changes to ESG Disclosures Introduced by SEBI
In December 2024, the Securities and Exchange Board of India (SEBI) approved key decisions related to the BRSR Core framework, ESG disclosures for the value chain, and assurance requirements.
Competition Commission of India Introduces Draft Regulations on Predatory Pricing
India’s antitrust regulator, CCI, has unveiled draft regulations for 2025 to refine predatory pricing assessments, ensuring clearer guidelines for fair competition and regulatory transparency.
Pharmaceutical SMEs in India Gain Time to Meet Enhanced GMP Standards Under Revised Schedule M
India’s Union Ministry of Health and Family Welfare has extended the deadline for small- and medium-sized pharmaceutical companies to comply with revised GMP compliance under Schedule M to December 31, 2025, following industry appeals.
